As for single ICI (SICI), KEYNOTE 024 proved that pembrolizumab (PEM) significantly increased OS and progression-free survival (PFS) in advanced wild-type NSCLC patients with PD-L1 ≥50% (7, 8). The gene discussed is CD274; the disease is non-small cell lung carcinoma.